Ludwig E
Department of Medicine and Clinical Pharmacology, Péterfy Teaching Hospital, Budapest, Hungary.
Chemotherapy. 1998 Sep;44 Suppl 1:31-4. doi: 10.1159/000048462.
Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized study in Central and Eastern Europe has confirmed the excellent efficacy of cefixime in both children and adults. In 45 children with acute sinusitis and 50 with acute otitis media, once-daily cefixime in oral suspension resulted in clinical cure or improvement in 45 (100%) and 48 (96%) patients, respectively. In 60 adult patients with acute exacerbations of chronic bronchitis and 12 with pneumonia, cefixime 400 mg resulted in cure or improvement in 59 (98%) and 12 (100%) patients, respectively. Similarly, excellent efficacy was found in adults with urinary tract infections (UTI), with cure in 80 (94%) patients, improvement in 4 (5%), and failure in 1 (1%). Very good efficacy of cefixime was also demonstrated microbiologically, with eradication in 35 of 36 isolates from children, including all Streptococcus pneumoniae isolates, 40 of 45 isolates from patients with respiratory tract infections, and 64 of 71 isolates from patients with UTI.
头孢克肟正在西方国家迅速确立其作为一种具有多种适应证的强效广谱抗生素的地位。一项在中东欧开展的多国、非随机研究证实了头孢克肟在儿童和成人中均具有出色的疗效。在45例急性鼻窦炎患儿和50例急性中耳炎患儿中，口服混悬液剂型的头孢克肟每日一次给药，分别使45例（100%）和48例（96%）患儿实现了临床治愈或病情改善。在60例慢性支气管炎急性加重期成年患者和12例肺炎成年患者中，400毫克头孢克肟分别使59例（98%）和12例（100%）患者治愈或病情改善。同样，在成年尿路感染（UTI）患者中也发现了出色的疗效，80例（94%）患者治愈，4例（5%）患者病情改善，1例（1%）患者治疗失败。头孢克肟在微生物学方面也显示出很好的疗效，在36株来自儿童的分离菌株中有35株被清除，包括所有肺炎链球菌分离菌株；在45株来自呼吸道感染患者的分离菌株中有40株被清除；在71株来自UTI患者的分离菌株中有64株被清除。
